Wednesday, June 10, 2026
🇺🇸 FDA

Intelligence · Patents

Patents expiring in 2039

Annual patent cliff calendar for 2039 — US pharmaceutical patents by expiration date.

Patents
1,782

Quick answer

1,782 indexed pharmaceutical patents have expiration dates in 2039. Browse by soonest expiry with links to assignee companies and related drugs.

  1. US 10231947

    Isochroman compounds and methods of use thereof

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 10232041

    Combination of lenalidomide and polypeptide construct, and uses thereof

    TEVA PHARMACEUTICALS PTY LTD · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 10233174

    Thiocarbamate prodrugs of tofacitinib

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 10233206

    D-fagomine for the control of inflammatory processes related to an overactivation of the humoral immune response

    SERGIO PUMAROLA SEGURA · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 10232044

    Controlled release aural pressure modulator compositions and methods for the treatment of OTIC disorders

    The Regents of the University of California · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 10233142

    Metabolites of (1R-trans)-N-[[2-(2,3-dihydro-4-benzofuranyl)cyclopropyl]methyl]propanamide

    VANDA PHARMACEUTICALS INC. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 10232042

    Conjugates of an anti-TNF-alpha antibody

    Nektar Therapeutics · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 10232059

    Functionalized magnetic nanoparticles and use in imaging amyloid deposits and neurofibrillary tangles

    The Regents of the University of California · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 10233240

    Methods for treating cholestatic liver fibrosis

    The Regents of the University of California · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 10233172

    Benzimidazole-carboxamide compounds as 5-HT4 receptor agonists

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 10233420

    Methods of recellularizing a tissue or organ for improved transplantability

    Regents of the University of Minnesota · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 10233250

    Human antibodies to the glucagon receptor and methods of use thereof for lowering blood glucose or ketone levels

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 10231955

    Enhanced delivery of immunosuppressive drug compositions for pulmonary delivery

    The Board of Regents of the University of Texas System · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 10233438

    Engineered primate L-methioninase for therapeutic purposes

    The Board of Regents of the University of Texas System · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 10233463

    Neurotensin-induced tumor formation is regulated by micro RNA 133A-aftiphilin-dependent receptor recycling

    The Regents of the University of California · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 10233161

    Pharmaceutical compositions and salts of a 1,2,4-oxadiazole benzoic acid

    PTC THERAPEUTICS, INC. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 10233191

    Fused piperidine amides as modulators of ion channels

    Vertex Pharmaceuticals Incorporated · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 10233235

    Modulating the alternative complement pathway

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 10233450

    Methods and compositions for the specific inhibition of gene expression by double-stranded RNA

    INTEGRATED DNA TECHNOLOGIES, INC. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 10233222

    Methods, compositions, diagnostics and assays for the treatment of Alzheimer's disease

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 10233429

    Hand, foot, and mouth vaccines and methods of manufacture and use thereof

    Takeda Vaccines, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 10231929

    Solid dispersion

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 10231943

    Compositions and methods for treating cardiovascular diseases

    Infirst Healthcare Limited · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 10232035

    Conditionally replication deficient herpes virus and use thereof in vaccines

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 10233448

    Modified double-stranded RNA agents

    Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 10231905

    Dental curable composition

    KURARAY NORITAKE DENTAL INC. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 10233209

    Inhibitors of the farnesoid x receptor and uses in medicine

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 10233152

    LSD1 inhibitors

    Mirati Therapeutics, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 10233244

    Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereof

    CytomX Therapeutics, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 10231932

    Process of preparing pharmaceutical compositions for the treatment of CFTR mediated diseases

    Vertex Pharmaceuticals Incorporated · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 10233452

    Compositions and methods for increasing erythropoietin (EPO) production

    Alnylam Pharmaceuticals, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 10233170

    2,3-disubstituted pyridine compounds as TGF-beta inhibitors and methods of use

    Rigel Pharmaceuticals, Inc. · Granted Tue Mar 19 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 14 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. AU 2017305856

    Pharmaceutical formulations of C1 esterase inhibitor

    CSL BEHRING GMBH [DE] · Granted Thu Mar 21 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Wed Mar 16 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 10238618

    Compositions and methods for diagnosis and treatment of anemia

    United States of America as represented by the Secretary of the Air Force · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 10238606

    Pharmaceutical compositions for the treatment of Helicobacter pylori

    RedHill Biopharma Ltd. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 10238599

    Composition and method for treating congenital cytomegalovirus induced hearing loss

    THE REGENTS OF THE UNIVERSITY OF MICHIGAN · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 10238605

    Dry coated tablet

    Takeda Pharmaceutical Company Limited · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 10238652

    Compounds for treatment of cancer

    Curegenix, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 10238646

    Methods for treating pruritus

    Trevi Therapeutics, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 10240130

    CDNA clone-launched platform for high-yield production of inactivated zika virus

    The Board of Regents of the University of Texas System · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 10239832

    N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 10238698

    Biomarkers and combination therapies using oncolytic virus and immunomodulation

    The Board of Regents of the University of Texas System · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 10238642

    Methods for treating neurogenic orthostatic hypotension

    Theravance Biopharma R&D IP, LLC · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 10238626

    Therapeutic compounds

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 10239911

    Beta-D-2′-deoxy-2′-alpha-fluoro-2′-beta-C-substituted-2-modified-N6-substituted purine nucleotides for HCV treatment

    Atea Pharmaceuticals, Inc. · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 10238655

    Dihydroindene and tetrahydronaphthalene compounds

    ARIZONA BOARD OF REGENTS FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 10238659

    Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

    Corcept Therapeutics Incorporated · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 10238674

    Bovine milk oligosaccharides

    The Regents of the University of California · Granted Tue Mar 26 2019 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 21 2039 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many pharma patents expire in 2039?

1,782 published patents in our USPTO index have expiration dates falling in calendar year 2039.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.